Work

Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a Phase I clinical trial

Year: 2007

Type: article

Source: Molecular Cancer Therapeutics

Authors: Amita Patnaik, Patricia LoRusso, Josep Tabernero, A. Douglas Laird, Sanjay Aggarwal, Kyriakos P. Papadopoulos

Institutions: Wayne State University, South Texas Accelerated Research Therapeutics, Vall d'Hebron Hospital Universitari

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2261669934

FWCI: 0.359

Cites:

Cited by: 8

Related to: 20